Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
Clinical trial NCT01300156 · UNKNOWN
Trial details
- NCT number
- NCT01300156
- Sponsor
- National Cancer Center, Korea
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2013-06-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.